Swiss pharma giant Novartis (NYSE: NVS) has partnered with Beijing’s Changping district government to expand its business footprint in the region, focusing on novel drug development and digital health collaborations. The alliance will drive pilot projects and support local innovation in treatment technologies.
Partnership Details
Announced in an online meeting between Novartis CEO Vas Narasimhan and Beijing Mayor Chen Jining, the partnership aims to boost investment, manufacturing, and digital health initiatives in Changping. Novartis plans to file 50 new drug approvals/indications in China over the next five years, building on its 90+ drug approvals since entering the market in 1987.
Strategic Commitments
Narasimhan pledged to enhance R&D and manufacturing capacities in Beijing, aligning with China’s push for advanced healthcare solutions. The collaboration underscores Novartis’ commitment to addressing local medical needs through innovation.-Fineline Info & Tech
